SCHEMBL22042474

SCHEMBL22042474

COc1cc(Cl)nnc1N1CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.39
CHRNB2 P17787 1/20 0.38
CHRNA4 P43681 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GFER P55789 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 1/20 0.36
STAT6 P42226 1/20 0.36
CYP1A2 P05177 1/20 0.36
ENPP1 P22413 1/20 0.36
ATM Q13315 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31092659 1.00 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1LMNACHRNB2CHRNA4
SCHEMBL31000090 0.85 SMN1; SMN2 (0.53) SMN1; SMN2ALDH1A1LMNAKMT2APDE4A
SCHEMBL12002995 0.83 SUV39H2 (0.41) SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2
SCHEMBL31000161 0.83 PDE5A (0.42) SMN1; SMN2ALDH1A1LMNAATMPDE5A
SCHEMBL31000267 0.79 ENPP1 (0.36) SMN1; SMN2ALDH1A1LMNAENPP1ATM
SCHEMBL23912350 0.77 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1MEN1KMT2APDE4A
SCHEMBL29682805 0.75 ATM (0.41) SMN1; SMN2ALDH1A1LMNANPSR1HTT
SCHEMBL24542645 0.75 ATM (0.41) SMN1; SMN2ALDH1A1LMNANPSR1HTT
SCHEMBL31000116 0.74 TP53 (0.38) SMN1; SMN2LMNAPDE4AATM
SCHEMBL20582119 0.74 MALT1 (0.34) ALDH1A1LMNAMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528822-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-01-20 US disclosed
US-12060365-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2024-08-13 US disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 EP disclosed
EP-3892278-B1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2024-02-28 EP disclosed
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-09 US disclosed
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-03-09 US disclosed
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-02 US disclosed
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-02-02 US disclosed
US-11236106-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-02-01 US disclosed
US-11236106-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-02-01 US disclosed
EP-3892278-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-10-13 EP disclosed
EP-3892278-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-10-13 EP disclosed
CN-113164481-A Cycloalkane-1, 3-diamine derivatives 第一三共株式会社 2021-07-23 CN disclosed
WO-2020116662-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE 第一三共株式会社 2020-06-11 WO disclosed
WO-2020116662-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE 第一三共株式会社 2020-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236106-B2 Cycloalkane-1,3-diamine derivative MLLT1, MEN1, MLLT3 SMN1; SMN2 1327/4885ALDH1A1 3327/4885LMNA 1180/4885
US-12060365-B2 Cycloalkane-1,3-diamine derivative MLLT1, MEN1, MLLT3 SMN1; SMN2 1327/4885ALDH1A1 3327/4885LMNA 1180/4885
US-20230030720-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE MLLT1, MEN1, MLLT3 SMN1; SMN2 1327/4885ALDH1A1 3327/4885LMNA 1180/4885
US-12528822-B2 Cycloalkane-1,3-diamine derivative MLLT1, MLLT3, PRMT6 SMN1; SMN2 1678/4885ALDH1A1 3230/4885LMNA 1233/4885
US-20230074669-A1 CYCLOALKANE-1,3-DIAMINE DERIVATIVE MLLT1, MEN1, MLLT3 SMN1; SMN2 1327/4885ALDH1A1 3327/4885LMNA 1180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.